[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

December 2018 - April 2015

Decade

Year

Issue

December 2018, Vol 4, No. 12, Pages 1635-1798

Original Investigation

Association of Analgesic Use With Risk of Ovarian Cancer in the Nurses’ Health Studies

Abstract Full Text
has audio
JAMA Oncol. 2018;4(12):1675-1682. doi:10.1001/jamaoncol.2018.4149

This cohort study uses data from the Nurses’ Health Studies to evaluate associations between use of nonsteroidal anti-inflammatory drugs and risk of epithelial ovarian cancer.

Association Between Aspirin Use and Risk of Hepatocellular Carcinoma

Abstract Full Text
has audio
JAMA Oncol. 2018;4(12):1683-1690. doi:10.1001/jamaoncol.2018.4154

This pooled analysis of the Nurses’ Health Study and the Health Professionals Follow-up Study examines the association between long-term use of aspirin and the development of hepatocellular carcinoma in adult men and women.

Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer

Abstract Full Text
JAMA Oncol. 2018;4(12):1691-1698. doi:10.1001/jamaoncol.2018.2805

This analysis of genomic data from The Cancer Genome Atlas and an Asian cohort investigates associations between MUC16 mutation, tumor mutation load, and survival in patients with gastric cancer.

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(12):1700-1706. doi:10.1001/jamaoncol.2018.2574

This secondary analysis of a randomized clinical trial investigates the association of circulating tumor cells with recurrence of breast cancer 5 or more years after diagnosis among patients with hormone receptor–positive breast cancer.

Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(12):1707-1712. doi:10.1001/jamaoncol.2018.3277

This single-arm, 2-stage, phase 2 clinical trial assesses the safety and efficacy of intravenous gemcitabine plus nanoparticle albumin-bound–paclitaxel for treatment of adults with advanced cholangiocarcinoma.

Comparison of Insurance Status and Diagnosis Stage Among Patients With Newly Diagnosed Cancer Before vs After Implementation of the Patient Protection and Affordable Care Act

Abstract Full Text
JAMA Oncol. 2018;4(12):1713-1720. doi:10.1001/jamaoncol.2018.3467

This population-based registry study of nonelderly patients with newly diagnosed cancer examines changes in the percentage of uninsured patients and stage at diagnosis before and after implementation of the Patient Protection and Affordable Care Act (ACA).

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923

This systematic review and meta-analysis analyzes the incidence of regimen-specific fatal toxic effects associated with the use of immune checkpoint inhibitors for cancer treatment.

Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(12):1729-1735. doi:10.1001/jamaoncol.2018.4005

This phase 1 clinical trial examines the escalation and safety of humanized anti-GD2 antibody doses in combination with granulocyte-macrophage colony-stimulating factor for treating patients with high-risk neuroblastoma.

Effect of Apoyo con Cariño (Support With Caring) Trial of a Patient Navigator Intervention to Improve Palliative Care Outcomes for Latino Adults With Advanced Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(12):1736-1741. doi:10.1001/jamaoncol.2018.4014

This randomized clinical trial investigates if a culturally tailored patient navigator intervention can improve palliative care outcomes for Latino patients with advanced cancer.

Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments

Abstract Full Text
JAMA Oncol. 2018;4(12):1742-1748. doi:10.1001/jamaoncol.2018.4292

This survey study of patients undergoing radiotherapy for cancer compares clinician advice against using topical agents before radiotherapy to avoid an increased radiation dose to the skin with the results of a dosimetric study and a preclinical study in an animal model.

Association of Transforming Growth Factor β Polymorphism C−509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(12):1751-1757. doi:10.1001/jamaoncol.2018.2583

This cohort study of female participants with stage 0 to IIA breast cancer treated with breast-conserving surgery and whole-breast irradiation assesses whether radiation-induced toxicities of normal breast tissue 3 years after radiotherapy are associated with the transforming growth factor β gene variant C−509T.

Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood

Abstract Full Text
online only
JAMA Oncol. 2018;4(12):e182453. doi:10.1001/jamaoncol.2018.2453

This cohort study examines cause-specific late mortality among individuals who have lived 2 years or more after allogeneic blood or marrow transplantation performed in childhood and whether rates of late mortality have changed over time.

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2018;4(12):e184060. doi:10.1001/jamaoncol.2018.4060

This phase 2, multi-institutional clinical trial assesses whether patients with resected primary gastrointestinal stromal tumor receiving 5 years of adjuvant imatinib mesylate therapy have improved recurrence-free survival and overall survival compared with patients receiving a shorter duration of therapy in previous studies.

Brief Report

Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2018;4(12):e183267. doi:10.1001/jamaoncol.2018.3267

This nonrandomized clinical trial examines the safety, tolerability, immunogenicity, and anti–multiple myeloma activity of the PVX-410 multipeptide vaccine with or without lenalidomide.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2018;4(12):e183486. doi:10.1001/jamaoncol.2018.3486

This randomized clinical trial assesses the efficacy and safety of continuous bevacizumab treatment plus standard of care vs standard of care alone beyond first progression in patients with non–small cell lung cancer.

Research Letter

The Use of “Trend” Statements to Describe Statistically Nonsignificant Results in the Oncology Literature

Abstract Full Text
JAMA Oncol. 2018;4(12):1778-1779. doi:10.1001/jamaoncol.2018.4524

This study examines recent original research articles in leading oncology journals to evaluate the use of statements about the trend of a P value toward significance to describe statistically nonsignificant results.

Early Adoption of Biosimilar Growth Factors in Supportive Cancer Care

Abstract Full Text
JAMA Oncol. 2018;4(12):1779-1781. doi:10.1001/jamaoncol.2018.5090

This retrospective observational analysis of health claims data compares the safety, effectiveness, and cost of biosimilar filgrastim and filgrastim.

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2018;4(12):1781-1783. doi:10.1001/jamaoncol.2018.5457

This 5-year follow-up of a phase 2 clinical trial assesses long-term durability of minimal residual disease–negative remission and time to disease progression among patients with newly diagnosed multiple myeloma who received triplet-based induction therapy with lenalidomide maintenance therapy.

Review

Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review

Abstract Full Text
JAMA Oncol. 2018;4(12):1765-1772. doi:10.1001/jamaoncol.2018.4044

This narrative review describes targeted alpha therapy and reviews the rationale and considerations for its development and implementation as a viable treatment strategy in oncology.

JAMA Oncology Clinical Challenge

A Poorly Differentiated Lung Malignancy in a Young Adult

Abstract Full Text
has active quiz
JAMA Oncol. 2018;4(12):1773-1774. doi:10.1001/jamaoncol.2018.2648

A man in his early 20s presented with a history of smoking, shortness of breath, pleuritic chest pain, and a dense consolidation in the right lung. What is your diagnosis?

Viewpoint

Reassessment of 4-Cycle Etoposide and Cisplatin as the Standard of Care for Good-Risk Metastatic Germ Cell Tumors

Abstract Full Text
JAMA Oncol. 2018;4(12):1661-1662. doi:10.1001/jamaoncol.2018.4316

This Viewpoint assesses the current recommendation of treatment regimens with and without bleomycin for patients with metastatic germ cell tumors of the testis.

Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening

Abstract Full Text
JAMA Oncol. 2018;4(12):1663-1664. doi:10.1001/jamaoncol.2018.4160

This Viewpoint addresses whether there is sufficient evidence to support routine use of multiparametric magnetic resonance imaging as an adjunctive test for men with elevated prostate-specific antigen level and considers the practical implications of its widespread implementation.

How Pharmacy Benefit Managers Add to Financial Toxicity: The Copay Accumulator Program

Abstract Full Text
JAMA Oncol. 2018;4(12):1665-1666. doi:10.1001/jamaoncol.2018.4554

This Viewpoint examines the role of benefit managers and other mechanisms driving the sustained increases in prescription drug costs in the United States.

Editorial

Aspirin and Chemoprevention—Have We Arrived?

Abstract Full Text
JAMA Oncol. 2018;4(12):1668-1669. doi:10.1001/jamaoncol.2018.4138
Invited Commentary

MUC16 Mutations and Prognosis in Gastric Cancer: A Little Goes a Long Way

Abstract Full Text
JAMA Oncol. 2018;4(12):1698-1699. doi:10.1001/jamaoncol.2018.2803

Avoiding Topical Agents Before Daily Radiotherapy: Debunking Dogma

Abstract Full Text
JAMA Oncol. 2018;4(12):1748-1750. doi:10.1001/jamaoncol.2018.4291
JAMA Oncology Patient Page

Clinical Trials, End Points, and Statistics—Measuring and Comparing Cancer Treatments in Practice

Abstract Full Text
free access
JAMA Oncol. 2018;4(12):1798. doi:10.1001/jamaoncol.2018.3708

This Patient Page defines the some of the important terms and techniques that cancer researchers use to measure and report their findings.

Cancer Care Chronicles

Surviving Cancer in the Midst of a Treatment Revolution: Hope and Delusion

Abstract Full Text
JAMA Oncol. 2018;4(12):1667. doi:10.1001/jamaoncol.2018.4430

In this article, the author discusses his struggles with hope and delusion in his personal experience with renal cell carcinoma.

Poetry and Oncology

White Noise

Abstract Full Text
JAMA Oncol. 2018;4(12):1793. doi:10.1001/jamaoncol.2018.4644
Comment & Response

Cognitive Impairment Among Older Patients With Hematologic Cancers

Abstract Full Text
JAMA Oncol. 2018;4(12):1783-1784. doi:10.1001/jamaoncol.2018.4594

Cognitive Impairment Among Older Patients With Hematologic Cancers—Reply

Abstract Full Text
JAMA Oncol. 2018;4(12):1784. doi:10.1001/jamaoncol.2018.4654

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy

Abstract Full Text
JAMA Oncol. 2018;4(12):1784-1785. doi:10.1001/jamaoncol.2018.4625

Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy—Reply

Abstract Full Text
JAMA Oncol. 2018;4(12):1785-1786. doi:10.1001/jamaoncol.2018.4657

Progestin, Not Progesterone

Abstract Full Text
JAMA Oncol. 2018;4(12):1786. doi:10.1001/jamaoncol.2018.4637

Pacritinib in Patients With Myelofibrosis

Abstract Full Text
JAMA Oncol. 2018;4(12):1786-1787. doi:10.1001/jamaoncol.2018.4830

Pacritinib in Patients with Myelofibrosis—Reply

Abstract Full Text
JAMA Oncol. 2018;4(12):1787. doi:10.1001/jamaoncol.2018.4842

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer

Abstract Full Text
JAMA Oncol. 2018;4(12):1787-1788. doi:10.1001/jamaoncol.2018.4931

Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

Abstract Full Text
JAMA Oncol. 2018;4(12):1788. doi:10.1001/jamaoncol.2018.4959

Moving Precision Oncology Forward Amid Myths and Misconceptions

Abstract Full Text
JAMA Oncol. 2018;4(12):1788-1789. doi:10.1001/jamaoncol.2018.5064

Moving Precision Oncology Forward Amid Myths and Misconceptions

Abstract Full Text
JAMA Oncol. 2018;4(12):1789-1790. doi:10.1001/jamaoncol.2018.5067

Moving Precision Oncology Forward Amid Myths and Misconceptions—Reply

Abstract Full Text
JAMA Oncol. 2018;4(12):1790. doi:10.1001/jamaoncol.2018.5111

Focus on the Number of Radiation Oncology Trials or on Clinical Relevance?

Abstract Full Text
JAMA Oncol. 2018;4(12):1791. doi:10.1001/jamaoncol.2018.5116

Focus on the Number of Radiation Oncology Trials or on Clinical Relevance—Reply

Abstract Full Text
JAMA Oncol. 2018;4(12):1791-1792. doi:10.1001/jamaoncol.2018.5105
Correction

Incorrect Surnames in Byline

Abstract Full Text
free access
JAMA Oncol. 2018;4(12):1792. doi:10.1001/jamaoncol.2018.5229

Error in Figure 1

Abstract Full Text
free access
JAMA Oncol. 2018;4(12):1792. doi:10.1001/jamaoncol.2018.5346

Error in Figure 2

Abstract Full Text
free access
JAMA Oncol. 2018;4(12):1792. doi:10.1001/jamaoncol.2018.6227
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2018;4(12):1641. doi:10.1001/jamaoncol.2017.3264
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2018;4(12):1635. doi:10.1001/jamaoncol.2017.3263
×